EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC 4.0

The efficacy of the levonorgestrel intrauterine system versus oral megestrol acetate in treating atypical endometrial hyperplasia: a superior randomized controlled trial

Amr A Alnemr iD, Ola A Harb iD, Hytham Atia iD

Journal of Gynecologic Oncology · 2024 · 35 (5)

DOI: 10.3802/jgo.2024.35.e62 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Amr A Alnemr und 2 weiteren Autor:innen. Beteiligte Einrichtung: Obstetrics & Gynecology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt. Hauptthemen laut MEDLINE: Levonorgestrel, Endometrial Hyperplasia, Megestrol Acetate, Intrauterine Devices, Medicated. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To compare the efficacy of the levonorgestrel intrauterine system (LNG-IUS) versus megestrol acetate (MA) in inducing complete regression among women with atypical endometrial hyperplasia (AEH) who declined hysterectomy. METHODS: In this single-center, open-label randomized controlled trial, we included 148 women with AEH who declined hysterectomy. We randomized participants to receive either daily oral MA 160 mg (n=74) or apply LNG-IUS (n=74) and scheduled their follow-up by endometrial sampling at 3, 6, 9, 12, 18, and 24 months. The success rate and duration until complete regression were the primary outcomes. RESULTS: The mean duration until complete regression was 5.52 months (95% confidence interval [CI]=4.85-6.18) for the LNG-IUS group versus 6.87 months (95% CI=6.09-7.64) for the megestrol group (log-rank test p-value=0.011). The cumulative regression rate after 12 months was 91.9% with the LNG-IUS versus 77% with MA (p=0.026). Weight gain in the MA group vs LNG-IUS group after one year (4.7±4 kg vs. 2.7±2.6 kg, 95% CI=0.89-3.12; p=0.001) and after two years of therapy (7.8±5.1 kg vs. 4.1±2.9 kg, 95% CI=2.29-5.06; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevonorgestrelEndometrial HyperplasiaMegestrol AcetateIntrauterine Devices, MedicatedHumansFemaleMiddle AgedAdultAdministration, OralTreatment Outcome

Stichwörter der Autor:innen

Atypical Endometrial HyperplasiaIntrauterine Devices, Progesterone-ReleasingMegestrol AcetateUterine Bleeding

Substanzen

LevonorgestrelMegestrol Acetate

Autor:innen und Institutionen

  • Obstetrics & Gynecology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
  • Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
  • Obstetrics & Gynecology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt. hythamatia@gmail.com.

ORCID-Profile: Amr A Alnemr, Ola A Harb, Hytham Atia

Zitieren

APA

Alnemr, A. A., Harb, O. A., & Atia, H. (2024). The efficacy of the levonorgestrel intrauterine system versus oral megestrol acetate in treating atypical endometrial hyperplasia: a superior randomized controlled trial. Journal of Gynecologic Oncology, 35(5). https://doi.org/10.3802/jgo.2024.35.e62

Vancouver

Alnemr AA, Harb OA, Atia H. The efficacy of the levonorgestrel intrauterine system versus oral megestrol acetate in treating atypical endometrial hyperplasia: a superior randomized controlled trial. Journal of Gynecologic Oncology. 2024;35(5). doi:10.3802/jgo.2024.35.e62

BibTeX
@article{Alnemr2024,
  author = {Alnemr, Amr A and Harb, Ola A and Atia, Hytham},
  title = {The efficacy of the levonorgestrel intrauterine system versus oral megestrol acetate in treating atypical endometrial hyperplasia: a superior randomized controlled trial},
  journal = {Journal of Gynecologic Oncology},
  year = {2024},
  volume = {35},
  number = {5},
  doi = {10.3802/jgo.2024.35.e62}
}
Kostenlos starten →